| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 14/12/2023 | 14:18 | PR Newswire (Canada) | L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - AEZS | TSX:AEZS | Aeterna Zentaris Inc |
| 14/12/2023 | 14:16 | PR Newswire (Canada) | Canadian Investment Regulatory Organization Trade Resumption - AEZS | TSX:AEZS | Aeterna Zentaris Inc |
| 14/12/2023 | 14:14 | PR Newswire (Canada) | Suspension de la négociation par l'Organisme canadien de réglementation des investissements - AEZS | TSX:AEZS | Aeterna Zentaris Inc |
| 14/12/2023 | 14:12 | PR Newswire (Canada) | Canadian Investment Regulatory Organization Trading Halt - AEZS | TSX:AEZS | Aeterna Zentaris Inc |
| 13/03/2019 | 12:53 | PR Newswire (Canada) | L'OCRCVM permet la reprise de la négociation - AEZS | TSX:AEZS | Aeterna Zentaris Inc |
| 13/03/2019 | 12:52 | PR Newswire (Canada) | IIROC Trade Resumption - AEZS | TSX:AEZS | Aeterna Zentaris Inc |
| 12/03/2019 | 20:32 | PR Newswire (Canada) | Suspension de la négociation par l'OCRCVM - AEZS | TSX:AEZS | Aeterna Zentaris Inc |
| 12/03/2019 | 20:27 | PR Newswire (Canada) | IIROC Trading Halt - AEZS | TSX:AEZS | Aeterna Zentaris Inc |
| 21/12/2017 | 14:26 | PR Newswire (Canada) | L'OCRCVM permet la reprise de la négociation - AEZS; BNE | TSX:AEZS | Aeterna Zentaris Inc |
| 21/12/2017 | 14:23 | PR Newswire (Canada) | IIROC Trade Resumption - AEZS; BNE | TSX:AEZS | Aeterna Zentaris Inc |
| 03/02/2010 | 14:35 | PR Newswire (US) | AEterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-040 | NASDAQ:AEZS | |
| 29/01/2010 | 14:35 | PR Newswire (US) | AEterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced | NASDAQ:AEZS | |
| 29/01/2010 | 14:30 | PR Newswire (US) | Keryx Biopharmaceuticals Announces Positive Phase 2 Study Results of Perifosine as a Single Agent for the Treatment of Advanced | NASDAQ:AEZS | |
| 27/01/2010 | 22:00 | PR Newswire (US) | Keryx Biopharmaceuticals, Inc. to Conduct Conference Call to Discuss KRX-0401 (Perifosine) Clinical Development Program in Color | NASDAQ:AEZS | |
| 25/01/2010 | 14:35 | PR Newswire (US) | AEterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Dou | NASDAQ:AEZS | |
| 25/01/2010 | 14:30 | PR Newswire (US) | Keryx Reports Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controll | NASDAQ:AEZS | |
| 22/01/2010 | 22:05 | PR Newswire (US) | AEterna Zentaris Receives NASDAQ Notification Related to Minimum Bid Price | NASDAQ:AEZS | |
| 21/01/2010 | 14:35 | PR Newswire (US) | AEterna Zentaris Partner, Keryx Biopharmaceuticals, to Present Poster Highlighting Clinical Activity of Perifosine (KRX-0401) at | NASDAQ:AEZS | |
| 21/01/2010 | 14:30 | PR Newswire (US) | Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the ASCO 2010 | NASDAQ:AEZS | |
| 18/12/2009 | 13:15 | PR Newswire (US) | AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensin | NASDAQ:AEZS | |
| 16/12/2009 | 14:35 | PR Newswire (US) | AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients w | NASDAQ:AEZS | |
| 09/12/2009 | 13:30 | PR Newswire (US) | AEterna Zentaris Announces Appointment of New Board Member | NASDAQ:AEZS | |
| 07/12/2009 | 14:35 | PR Newswire (US) | AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Tr | NASDAQ:AEZS | |
| 07/12/2009 | 14:30 | PR Newswire (US) | Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Trea | NASDAQ:AEZS | |
| 07/12/2009 | 13:40 | PR Newswire (US) | AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia | NASDAQ:AEZS | |
| 02/12/2009 | 14:35 | PR Newswire (US) | AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed | NASDAQ:AEZS | |
| 02/12/2009 | 14:30 | PR Newswire (US) | Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma | NASDAQ:AEZS | |
| 24/11/2009 | 13:00 | PR Newswire (US) | AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endome | NASDAQ:AEZS | |
| 11/11/2009 | 14:35 | PR Newswire (US) | AEterna Zentaris Partner, Keryx Biopharmaceuticals, Announces Poster Presentation Highlighting Clinical Activity of Perifosine ( | NASDAQ:AEZS | |
| 11/11/2009 | 14:30 | PR Newswire (US) | Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annua | NASDAQ:AEZS | |